16.4
镇静剂是缓解焦虑的药物,而催眠药则诱导睡眠。这两类药物都会抑制神经元活动,镇静剂具有镇静作用,催眠药则有助于睡眠。
镇静催眠药分为巴比妥类、苯二氮卓类 (BZD) 和非苯二氮卓类或 Z 类药物。这些药物通过抑制中枢神经系统活动起作用,这种抑制作用与剂量有关。较旧的镇静药物,如巴比妥类药物,其剂量反应…
镇静剂属于一类能够使个体镇静的药物,而催眠药则用于诱导并维持睡眠。这两类药物均通过减缓大脑活动发挥作用。
镇静催眠药物以剂量依赖性方式抑制中枢神经系统活动。较早的药物如巴比妥类药物遵循线性剂量-效应曲线,可能具有致命风险。而 newer 药物如苯二氮䓬类药物则偏离线性曲线,因此适用于短期缓解。
镇静催眠药物主要作用于GABAA配体门控离子通道和褪黑素GPCR。
神经递质GABA结合并打开GABAA离子通道,允许氯离子内流,降低静息电位,从而抑制神经元放电。
巴比妥类药物、苯二氮䓬类药物以及唑吡坦等新型药物在GABA受体上的不同变构位点结合A 通道,促进GABA结合及神经元抑制。
此外,褪黑激素可激活下丘脑前部的MT1和MT2 GPCR,降低神经元放电,促进睡眠。褪黑激素类似物(如雷美尔通)对失眠有帮助,且无依赖风险。
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between sedatives and hypnotics?
Sedatives calm individuals by reducing anxiety, while hypnotics induce and maintain sleep. Both work by slowing brain activity and suppressing central nervous system activity in a dose-dependent manner. The key distinction lies in their primary effect: sedatives provide calming relief, whereas hypnotics facilitate sleep onset and continuation.
Q2: How do sedative-hypnotic drugs affect the brain at the molecular level?
Sedative-hypnotic drugs primarily target GABAA ligand-gated ion channels and melatonin GPCRs. When GABA binds to GABAA channels, chloride ions flow in, decreasing neuronal resting potential and inhibiting firing. Barbiturates, benzodiazepines, and zolpidem bind at different allosteric sites on GABAA channels, promoting GABA binding and enhancing neuronal suppression.
Q3: Why are barbiturates considered more dangerous than benzodiazepines?
Barbiturates follow a linear dose-response curve, meaning CNS depression increases proportionally with dose, potentially causing fatal overdose. Benzodiazepines deviate from this linear curve, providing a safety margin where only extremely high doses cause severe CNS depression. This non-linear relationship makes sedatives and hypnotics drugs benzodiazepines safer for short-term anxiety and sleep relief.
Q4: What role do melatonin receptors play in sleep induction?
Melatonin activates MT1 and MT2 GPCRs in the anterior hypothalamus, decreasing neuronal firing and promoting sleep. Melatonin analogs like ramelteon mimic these effects and are helpful for treating insomnia without dependency risk. This receptor-based mechanism offers an alternative to GABA-targeting drugs for sleep management.
Q5: How do different sedative-hypnotic drug classes bind to GABAA channels?
Barbiturates, benzodiazepines, and non-benzodiazepine drugs such as zolpidem bind at different allosteric sites on the GABAA channel. By binding to these distinct sites, each drug class promotes GABA binding and enhances the inhibitory effect on neurons. This differential binding explains why sedatives and hypnotics drugs miscellaneous agents have unique pharmacological profiles and clinical applications.
Q6: What determines the safety profile of sedative-hypnotic medications?
The dose-response relationship determines safety. Older medications like barbiturates follow a linear curve with narrow safety margins, while newer drugs like benzodiazepines have non-linear dose-response relationships, providing wider safety margins. Careful dosage consideration and patient response monitoring are vital for ensuring safe and beneficial effects of sedative-hypnotic medications.
Q7: What are the main categories of sedative-hypnotic drugs available?
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs like zolpidem. Each category targets different molecular sites and has distinct pharmacological properties. Understanding these categories helps healthcare professionals select appropriate medications based on patient needs, duration of treatment, and safety considerations.